Association between oral contraceptive use as a risk factor and triple-negative breast cancer: A systematic review and meta-analysis

Li,Li; Zhong,Yahua; Zhang,Hongyan; Yu,Haijun; Huang,Yong; Li,Zheng; Chen,Gaili; Hua,Xinying

doi:10.3892/mco.2017.1259

Association between oral contraceptive use as a risk factor and triple-negative breast cancer: A systematic review and meta-analysis

Authors:
- Li Li
- Yahua Zhong
- Hongyan Zhang
- Haijun Yu
- Yong Huang
- Zheng Li
- Gaili Chen
- Xinying Hua
View Affiliations

Affiliations: Department of Radiation and Medical Oncology, Zhongnan Hospital, Wuhan University, Wuhan, Hubei 430071, P.R. China
Published online on: May 12, 2017 https://doi.org/10.3892/mco.2017.1259
Pages: 76-80

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Triple-negative breast cancer (TNBC), a unique subtype of breast cancer, which is resistant to endocrine and targeted therapy, usually relapses early, progresses rapidly and is associated with a poor prognosis. Epidemiological investigations focusing on the association between risk factors and the onset of TNBC demonstrated that the incidence of TNBC exhibits a significant correlation with anthropometric, geographical and demographic parameters. The aim of the present systematic review and meta-analysis was to evaluate the strength of the association between the use of oral contraceptives (OCs) and TNBC. Two databases (PubMed Central/PubMed, Web of Science) and secondary references were searched to identify studies meeting the priorly established inclusion criteria. Case-control studies published between January, 2005 and March, 2016 were searched using the key words (triple-negative breast cancer OR basal-like) AND (oral contraceptives). Finally, 9 eligible articles using as control other subtypes of invasive breast cancer and 7 articles using a healthy population as control were incorporated in the meta-analysis. Pooled odds ratio (OR) and 95% confidence interval (CI) were calculated using fixed- or random‑effects models according to the heterogeneity between studies. The case-control comparison using other subtypes of breast cancer as the control arm exhibited a significant association between OC use and TNBC (OR = 1.31, 95% CI = 1.18-1.45; Z=5.26, P<0.00001). These results were further confirmed by the case‑control comparison using the healthy population as the control arm (OR = 1.21, 95% CI = 1.01-1.46; Z=2.04, P=0.04). The present meta-analysis indicated that women who use OCs have a greater risk of TNBC compared with women who do not. This conclusion prompts that women who used OCs should be examined more closely in population screenings of breast cancer, as they may benefit from prevention and early detection strategies.

View Figures

View References

1	Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin. 58:71–96. 2008. View Article : Google Scholar : PubMed/NCBI
2	Rakha EA and Ellis IO: Triple-negative/basal-like breast cancer: review. Pathology. 41:40–47. 2009. View Article : Google Scholar : PubMed/NCBI
3	Huo D, Ikpatt F, Khramtsov A, Dangou JM, Nanda R, Dignam J, Zhang B, Grushko T, Zhang C, Oluwasola O, et al: Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol. 27:4515–4521. 2009. View Article : Google Scholar : PubMed/NCBI
4	Lv M, Li B, Li Y, Mao X, Yao F and Jin F: Predictive role of molecular subtypes in response to neoadjuvant chemotherapy in breast cancer patients in Northeast China. Asian Pac J Cancer Prev. 12:2411–2417. 2011.PubMed/NCBI
5	Dawood S, Lei X, Litton JK, Buchholz TA, Hortobagyi GN and Gonzalez-Angulo AM: Impact of body mass index on survival outcome among women with early stage triple-negative breast cancer. Clin Breast Cancer. 12:364–372. 2012. View Article : Google Scholar : PubMed/NCBI
6	de Giorgi U, Rosti G, Frassineti L, Kopf B, Giovannini N, Zumaglini F and Marangolo M: High-dose chemotherapy for triple negative breast cancer. Ann Oncol. 18:202–203. 2007. View Article : Google Scholar : PubMed/NCBI
7	Brady-West DC and McGrowder DA: Triple negative breast cancer: therapeutic and prognostic implications. Asian Pac J Cancer Prev. 12:2139–2143. 2011.PubMed/NCBI
8	Choi J, Jung WH and Koo JS: Clinicopathologic features of molecular subtypes of triple negative breast cancer based on immunohistochemical markers. Histol Histopathol. 27:1481–1493. 2012.PubMed/NCBI
9	Vaklavas C and Forero-Torres A: How do I treat ‘triple-negative’ disease. Curr Treat Options Oncol. 12:369–388. 2011. View Article : Google Scholar : PubMed/NCBI
10	de Ruijter TC, Veeck J, De Hoon JP, van Engeland M and Tjan-Heijnen VC: Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol. 137:183–192. 2011. View Article : Google Scholar : PubMed/NCBI
11	Irvin WJ Jr and Carey LA: What is triple-negative breast cancer? Eur J Cancer. 44:2799–2805. 2008. View Article : Google Scholar : PubMed/NCBI
12	Foulkes WD, Smith IE and Reis-Filho JS: Triple-negative breast cancer. N Engl J Med. 363:1938–1948. 2010. View Article : Google Scholar : PubMed/NCBI
13	Brenton JD, Carey LA, Ahmed AA and Caldas C: Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol. 23:7350–7360. 2005. View Article : Google Scholar : PubMed/NCBI
14	Stang A: Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 25:603–605. 2010. View Article : Google Scholar : PubMed/NCBI
15	Pierobon M and Frankenfeld CL: Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis. Breast Cancer Res Treat. 137:307–314. 2013. View Article : Google Scholar : PubMed/NCBI
16	Rosenberg L, Zhang Y, Coogan PF, Strom BL and Palmer JR: A case-control study of oral contraceptive use and incident breast cancer. Am J Epidemiol. 169:473–479. 2009. View Article : Google Scholar : PubMed/NCBI
17	Sutton AJ, Abrams KR, Jones DR, Sheldon TA and Song F: Methods for meta-analysis in medical researchStatistics in Medicine. Schwarzer and Guido: 22. John Wiley & Sons, Inc.; pp. 3112–3114. 2003, View Article : Google Scholar
18	Beaber EF, Malone KE, Tang MT, Barlow WE, Porter PL, Daling JR and Li CI: Oral contraceptives and breast cancer risk overall and by molecular subtype among young women. Cancer Epidemiol Biomarkers Prev. 23:755–764. 2014. View Article : Google Scholar : PubMed/NCBI
19	Bethea TN, Rosenberg L, Hong CC, Troester MA, Lunetta KL, Bandera EV, Schedin P, Kolonel LN, Olshan AF, Ambrosone CB and Palmer JR: A case-control analysis of oral contraceptive use and breast cancer subtypes in the African American Breast Cancer Epidemiology and Risk Consortium. Breast Cancer Res. 17:222015. View Article : Google Scholar : PubMed/NCBI
20	Dolle JM, Daling JR, White E, Brinton LA, Doody DR, Porter PL and Malone KE: Risk factors for triple-negative breast cancer in women under the age of 45 years. Cancer Epidemiol Biomarkers Prev. 18:1157–1166. 2009. View Article : Google Scholar : PubMed/NCBI
21	Lee E, McKean-Cowdin R, Ma H, Spicer DV, Van Den Berg D, Bernstein L and Ursin G: Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women. J Clin Oncol. 29:4373–4380. 2011. View Article : Google Scholar : PubMed/NCBI
22	Kabat GC, Kim M, Phipps AI, Li CI, Messina CR, Wactawski-Wende J, Kuller L, Simon MS, Yasmeen S, Wassertheil-Smoller S and Rohan TE: Smoking and alcohol consumption in relation to risk of triple-negative breast cancer in a cohort of postmenopausal women. Cancer Causes Control. 22:775–783. 2011. View Article : Google Scholar : PubMed/NCBI
23	Kwan ML, Kushi LH, Weltzien E, Maring B, Kutner SE, Fulton RS, Lee MM, Ambrosone CB and Caan BJ: Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res. 11:R312009. View Article : Google Scholar : PubMed/NCBI
24	Ma H, Wang Y, Sullivan-Halley J, Weiss L, Marchbanks PA, Spirtas R, Ursin G, Burkman RT, Simon MS, Malone KE, et al: Use of four biomarkers to evaluate the risk of breast cancer subtypes in the womens contraceptive and reproductive experiences study. Cancer Res. 70:575–587. 2010. View Article : Google Scholar : PubMed/NCBI
25	Kawai M, Malone KE, Tang MTC and Li CI: Active smoking and the risk of estrogen receptor-positive and triple-negative breast cancer among women ages 20 to 44 years. Cancer. 120:1026–1034. 2014. View Article : Google Scholar : PubMed/NCBI
26	Lara-Medina F, Pérez-Sánchez V, Saavedra-Pérez D, Blake-Cerda M, Arce C, Motola-Kuba D, Villarreal-Garza C, González-Angulo AM, Bargalló E, Aguilar JL, et al: Triple-negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity. Cancer. 117:3658–3669. 2011. View Article : Google Scholar : PubMed/NCBI
27	Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Dressler LG, Smith LV, Labbok MH, Geradts J, Bensen JT, et al: Epidemiology of basal-like breast cancer. Breast Cancer Res Treat. 109:123–139. 2008. View Article : Google Scholar : PubMed/NCBI
28	Phipps AI, Chlebowski RT, Prentice R, McTiernan A, Wactawski-Wende J, Kuller LH, Adams-Campbell LL, Lane D, Stefanick ML, Vitolins M, et al: Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. J Natl Cancer Inst. 103:470–477. 2011. View Article : Google Scholar : PubMed/NCBI
29	Marchbanks PA, Curtis KM, Mandel MG, Wilson HG, Jeng G, Folger SG, McDonald JA, Daling JR, Bernstein L, Malone KE, et al: Oral contraceptive formulation and risk of breast cancer. Contraception. 85:342–350. 2012. View Article : Google Scholar : PubMed/NCBI
30	Tariq K and Rana F: TNBC vs. non-TNBC: a five-year retrospective review of differences in mean age, family history, smoking history and stage at diagnosis at an inner city university program. World J Oncol. 4:241–247. 2013.
31	Phipps AI, Buist DSM, Malone KE, Barlow WE, Porter PL, Kerlikowske K and Li CI: Family history of breast cancer in first-degree relatives and triple-negative breast cancer risk. Breast Cancer Res Treat. 126:671–678. 2011. View Article : Google Scholar : PubMed/NCBI
32	Rosenberg L, Boggs DA, Wise LA, Adams-Campbell LL and Palmer JR: Oral contraceptive use and estrogen/progesterone receptor-negative breast cancer among African American women. Cancer Epidemiol Biomarkers Prev. 19:2073–2079. 2010. View Article : Google Scholar : PubMed/NCBI
33	Trivers KF, Lund MJ, Porter PL, Liff JM, Flagg EW, Coates RJ and Eley JW: The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control. 20:1071–1082. 2009. View Article : Google Scholar : PubMed/NCBI
34	Phipps AI, Malone KE, Porter PL, Daling JR and Li CI: Body size and risk of luminal, HER2-overexpressing, and triple-negative breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 17:2078–2086. 2008. View Article : Google Scholar : PubMed/NCBI
35	Rose DP and Vona-Davis L: Interaction between menopausal status and obesity in affecting breast cancer risk. Maturitas. 66:33–38. 2010. View Article : Google Scholar : PubMed/NCBI
36	Gupta PB, Proia D, Cingoz O, Weremowicz J, Naber SP, Weinberg RA and Kuperwasser C: Systemic stromal effects of estrogen promote the growth of estrogen receptor-negative cancers. Cancer Res. 67:2062–2071. 2007. View Article : Google Scholar : PubMed/NCBI